市場調查報告書
商品編碼
1087024

基因編輯的全球市場預測(2022年∼2027年)

Genome Editing Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球基因編輯的市場規模,從2020年的46億400萬美元,預計到2027年達到140億5,400萬美元,以17.29%的年複合成長率成長。

活用在農業和醫療領域,全球進行研究開發,對有解決各種問題的可能性的基因編輯技術的投資增加,預計在預測期間內的市場成長激增。此外,世界各地政府對提高作物的收穫量的基因編輯利用的支援,預計也是基因編輯市場的促進因素。

本報告提供全球基因編輯市場調查,市場概要,市場促進因素和阻礙因素,各技術、用途、終端用戶、地區的分析,競爭情形,企業簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析
    • 終端用戶談判力
    • 買主談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 產業的競爭情形
  • 產業的價值鏈分析

第5章 基因編輯市場分析:各技術

  • 簡介
  • CRISPR
  • TALEN
  • ZFN
  • 其他

第6章 基因編輯市場分析:各用途

  • 簡介
  • 細胞株工程
  • 動物基因工程學
  • 植物基因工程學

第7章 基因編輯市場分析:各終端用戶

  • 簡介
  • 學術、政府研究機關
  • 生物科技、製藥企業
  • 醫藥品臨床研究委外機構(CRO)

第8章 基因編輯市場分析:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第9章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業與市場的有利性
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第10章 企業簡介

  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Horizon Discovery Group plc
  • GenScript
  • Sangamo Therapeutics, Inc.
  • Integrated DNA Technologies, Inc.
  • Lonza Group Ltd.
  • BEX Co., LTD.
  • OriGene Technologies, Inc.
  • Transposagen Biopharmaceuticals, Inc.
目錄
Product Code: KSI061612981

The genome editing market was evaluated at US$4.604 billion in the year 2020 and is projected to grow at a CAGR of 17.29% to reach a market size of US$14.054 billion by the year 2027.

Genome editing is a method of making changes in a living organism's DNA and is used for improving crop yields, diagnosing and treating diseases, and for research purposes. The research and development in genome editing have been increasing worldwide as it is being used in the agriculture and healthcare sectors. Also, the investments in genome editing have been rising as the technique is being seen to have the potential to solve various problems, which is anticipated to surge the market growth during the forecast period. Furthermore, the support of various governments worldwide for the use of genome editing to improve crop yields is another prominent factor expected to drive the genome editing market. Moreover, the growing cases of cancer and other genetic disorders are surging the need for effective treatment and consequently leading to the market growth of genome editing.

The COVID-19 pandemic had a positive impact on the market as researchers developed new diagnostic tools based on CRISPR, a genome-editing technique, for diagnosing COVID-19 patients. This led to a positive impact on the genome editing market and increased the expected growth rates of the genome editing market in 2020 and 2021. As the spread of coronavirus continues to affect the world with its new waves and variants, the pandemic is projected to have a positive impact on the genome editing market in the coming years as well.

Growing cases of cancer and other genetic disorders

The cases of cancer and other genetic disorders have been increasing globally. The growing interest in genome editing for the treatment of cancer and several genetic disorders is anticipated to propel the growth of the genome editing market during the forecast period. NIH researchers have recently, in January 2021, found and recognized a new genetic disorder called linkage-specific-deubiquitylation-deficiency-induced embryonic defects syndrome (LINKED) that causes delays in development and hinders the proper formation of heart, facial features, and brain. Such identifications of new genetic disorders also contribute to the rising cases of genetic disorders. Furthermore, cancer cases have been proliferating. According to data from the International Agency for Research on Cancer (IARC), the number of cancer cases in the United Kingdom (England and Wales) has increased from 138,577 in 2010 to 156,444 in 2017 for males and from 130,674 in 2010 to 149,239 in 2017 for females. As per IARC, the number of cancer cases in Europe is projected to jump from 4.398 million in 2020 to 5.323 million in 2040, witnessing an increase of around 21%. In North America, the cases of cancer are projected to reach 3.525 million in 2040, increasing from 2.557 million in 2020, growing by nearly 38%. This is expected to have a positive impact on the genome editing market in the coming years, owing to an increasing need for better cancer treatments.

Rising investments and research in genome editing

In September 2021, the UK government announced its plans to support gene editing in agriculture to support the country's farmers in growing better and more productive crops. The government is making research and development easier. It also aims to make the necessary measures for genome-edited products to reach safely and responsibly to the market. Furthermore, the government of China is backing the use of CRISPR, a genome-editing technique, to improve the food supply in the country. In 2017, the state-owned company of China named ChemChina acquired Syngenta, a Switzerland-based agribusiness company working with CRISPR with an extensive research and development team. China spent $43 billion on the deal, which is the largest amount ever spent by China on buying a foreign company. The investments in genome editing are expected to grow further in the coming years, along with rising research and development, and are anticipated to boost the genome editing market growth during the forecast period.

North America to dominate the global market

Geographically, the North American region is anticipated to hold a significant market share owing to the large investments being made in the region in the field of genome editing. The Asia Pacific region is anticipated to witness substantial growth due to the surging cases of genetic disorders and cancer, along with higher spending on healthcare and research. As per the data from IARC, the number of cancer cases in Asia is projected to grow by more than 59%. Furthermore, the use of CRISPR has been increasing substantially in China, which is further expected to contribute to the market growth in the Asia Pacific.

Segmentation

  • By Technology

CRISPR

TALEN

ZFN

Others

  • By Application

Cell Line Engineering

Animal Genetic Engineering

Plant Genetic Engineering

  • By End-User

Academic & Government Research Institutes

Biotechnology & Pharmaceutical Companies

Contract Research Organizations

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • UK
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Genome Editing Market Analysis, by Technology

  • 5.1. Introduction
  • 5.2. CRISPR
  • 5.3. TALEN
  • 5.4. ZFN
  • 5.5. Others

6. Genome Editing Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Cell Line Engineering
  • 6.3. Animal Genetic Engineering
  • 6.4. Plant Genetic Engineering

7. Genome Editing Market Analysis, by End-User

  • 7.1. Introduction
  • 7.2. Academic & Government Research Institutes 
  • 7.3. Biotechnology & Pharmaceutical Companies
  • 7.4. Contract Research Organizations

8. Genome Editing Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

  • 10.1. Thermo Fisher Scientific Inc.
  • 10.2. Merck & Co., Inc.
  • 10.3. Horizon Discovery Group plc
  • 10.4. GenScript
  • 10.5. Sangamo Therapeutics, Inc.
  • 10.6. Integrated DNA Technologies, Inc.
  • 10.7. Lonza Group Ltd.
  • 10.8. BEX Co., LTD.
  • 10.9. OriGene Technologies, Inc.
  • 10.10. Transposagen Biopharmaceuticals, Inc.